The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Progression patterns and clinical outcomes after anti-PD-1 therapy failure in patients with cutaneous squamous cell carcinoma.
 
Karam Khaddour
No Relationships to Disclose
 
Pamela Kote
No Relationships to Disclose
 
Thomas Ohryn Doyle
No Relationships to Disclose
 
Jeffrey Guenette
No Relationships to Disclose
 
Jonathan Schoenfeld
Employment - Brigham and Women's Hospital
Stock and Other Ownership Interests - Immunitas; Intragel
Consulting or Advisory Role - EMD Serono; Immunitas; Merck KGaA
Research Funding - Bristol-Myers Squibb; EMD Serono/Merck; Merck; Regeneron; Siemens
Patents, Royalties, Other Intellectual Property - MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF; Nanobody bioconjugation for immune receptor targeting
Expert Testimony - Burns and White
 
Danielle Margalit
No Relationships to Disclose
 
Roy Tishler
No Relationships to Disclose
 
Eleni Rettig
Research Funding - Naveris
Other Relationship - Naveris
 
Rosh Sethi
No Relationships to Disclose
 
Donald Annino
No Relationships to Disclose
 
Laura Goguen
No Relationships to Disclose
 
Ravindra Uppaluri
Consulting or Advisory Role - Daichi-Sankyo; Merck; Regeneron
Research Funding - Daichi-Sankyo; Merck
Patents, Royalties, Other Intellectual Property - Washington University licenses mouse oral cancer cell lines made by my lab. I receive royalties from Washington University from these agreements.
 
Catherine Pisano
No Relationships to Disclose
 
Abigail Waldman
No Relationships to Disclose
 
Chrysalyne Schmults
No Relationships to Disclose
 
Emily Ruiz
No Relationships to Disclose
 
Justine Cohen
Consulting or Advisory Role - Bristol Myers Squibb; Incyte; Replimune
 
Ann Silk
Stock and Other Ownership Interests - gral; Illumina
Consulting or Advisory Role - Merck; Regeneron
Research Funding - Checkmate Pharmaceuticals (Inst); Merck (Inst); Morphogenesis (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Glenn Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; Elevar Therapeutics; Grey Wolf Therapeutics; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; PDS Biotechnology; Remix Therapeutics; Replimune; Surface Oncology
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); Kura Oncology (Inst); Regeneron (Inst); Secura Bio (Inst)